Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: the PLEASANT trial.
Julious SA, Horspool MJ, Davis S, Franklin M, Smithson WH, Norman P, Simpson RM, Elphick H, Bortolami O, Cooper C. Julious SA, et al. Among authors: horspool mj. BMJ Open. 2018 Apr 20;8(4):e017367. doi: 10.1136/bmjopen-2017-017367. BMJ Open. 2018. PMID: 29678962 Free PMC article. Clinical Trial.
PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluation.
Julious SA, Horspool MJ, Davis S, Bradburn M, Norman P, Shephard N, Cooper CL, Smithson WH, Boote J, Elphick H, Loban A, Franklin M, Kua WS, May R, Campbell J, Williams R, Rex S, Bortolami O. Julious SA, et al. Among authors: horspool mj. Health Technol Assess. 2016 Dec;20(93):1-154. doi: 10.3310/hta20930. Health Technol Assess. 2016. PMID: 28005003 Free PMC article. Clinical Trial.
Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial.
Selvarajah D, Petrie J, White D, Julious S, Bortolami O, Cooper C, Bradburn M, Loban A, Bowler H, Swaby L, Sutherland K, Tesfaye S; OPTION-DM group. Selvarajah D, et al. Trials. 2018 Oct 22;19(1):578. doi: 10.1186/s13063-018-2959-y. Trials. 2018. PMID: 30348206 Free PMC article.
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude EB, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Rice ASC, Bouhassira D, Bennett DL, Selvarajah D; OPTION-DM trial group. Tesfaye S, et al. Lancet. 2022 Aug 27;400(10353):680-690. doi: 10.1016/S0140-6736(22)01472-6. Epub 2022 Aug 22. Lancet. 2022. PMID: 36007534 Free PMC article. Clinical Trial.
Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Young T, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Julious SA, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude E, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Bouhassira D, Bennett DL, Selvarajah D. Tesfaye S, et al. Health Technol Assess. 2022 Oct;26(39):1-100. doi: 10.3310/RXUO6757. Health Technol Assess. 2022. PMID: 36259684 Free PMC article. Clinical Trial.
21 results